Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development
Portfolio Pulse from Lara Goldstein
Atai Life Sciences (NASDAQ:ATAI) has invested $50 million in Beckley Psytech Ltd. for the development of short-duration psychedelics for neuropsychiatric conditions. Atai now owns 35.5% of Beckley Psytech, which remains independent. The investment will accelerate the development of Beckley's psychedelic candidates, BPL-003 and ELE-101, with clinical trial results expected between H1 2024 and H2 2024. Atai's management believes in the potential of short-duration psychedelics to increase patient access and is building a large portfolio of psychedelic compounds. The collaboration may also explore digital tools for patient support and commercialization. GH Research (NASDAQ:GHRS) is also working with 5-MeO-DMT but is currently on clinical hold in the U.S.
January 04, 2024 | 7:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
GH Research is mentioned as a competitor to Atai in the development of 5-MeO-DMT treatments but is currently on clinical hold in the U.S., which could impact its progress in the market.
GH Research's current clinical hold in the U.S. is a setback that could delay its progress in developing 5-MeO-DMT treatments. This could negatively impact GHRS's stock price in the short term as investors may perceive Atai's investment in Beckley Psytech as a move to solidify its market position.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
Atai Life Sciences has made a strategic investment in Beckley Psytech to enhance its portfolio of psychedelic compounds and expects to benefit from the development of BPL-003 and ELE-101, with clinical trial results due in 2024.
The investment in Beckley Psytech is significant for Atai, as it not only increases its stake in the company but also potentially accelerates the development of promising psychedelic treatments. The positive anticipation of clinical trial results could drive investor interest and potentially increase Atai's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100